The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurgical Innovations Regulatory News (SUN)

Share Price Information for Surgical Innovations (SUN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.50
Bid: 0.40
Ask: 0.60
Change: 0.00 (0.00%)
Spread: 0.20 (50.00%)
Open: 0.50
High: 0.50
Low: 0.50
Prev. Close: 0.50
SUN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Product launch in partnership with CMR Surgical

21 Mar 2022 07:00

RNS Number : 3419F
Surgical Innovations Group PLC
21 March 2022
 

 

Surgical Innovations Group plc

("Surgical Innovations", "SI" or the "Company")

 

Product launch in partnership with CMR Surgical

Design agreement secured for a new surgical Resposable™ Port Access System

 

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces the launch of YelloPort™ Elite 5mm, a new surgical Port Access System, developed in partnership with CMR Surgical ('CMR'), a global medical devices company dedicated to transforming surgery with Versius®, a next-generation surgical robot. Under the design agreement Surgical Innovations and CMR have signed, the Company will supply the ResposableTM item for each installed CMR Surgical's Versius Robotic Systemâ.

 

The new YelloPort Elite™ 5mm product was designed specifically for CMR Surgical's Versius Robotic Systemâ, though it is universal in nature and can be used in combination with a wider range of laparoscopic instrumentation including other robotic systems. The device is designed to function effectively with robotic instrumentation and addresses the continuing need for high-quality cost-effective solutions within laparoscopy surgery, utilising the Company's ResposableTM technology to meet these clinical needs. YelloPort Elite™ 5mm received its CE mark in February 2022 and will be available globally from April 2022.

 

This is the first project that Surgical Innovations and CMR Surgical, two British-based medical device companies, have collaborated on. Both target international healthcare markets.

 

Mark Slack, Chief Medical Officer, CMR Surgical, said: "When we talk to hospitals and clinical teams, we hear how important it is for them to reduce the environmental impact of the surgical products and instruments they use. We want to partner with hospitals to reduce waste and cost, whilst advancing performance. Working with Surgical Innovations to develop this new port, for use with our robotic systems, we've been able to do just that."

 

David Marsh, Chief Executive Officer of Surgical Innovations, said: "We're delighted to partner with CMR Surgical, a fellow British medical device company focused in minimally invasive surgery, to develop this new surgical Port Access System. Our ResposableTM products provide a high-quality hybrid instrument concept, with the clinical benefits of a small disposable element, reducing waste by at least 70% compared to fully disposable alternatives. The project with CMR also creates opportunity to develop greater partnerships in robotic surgery and utilises our existing experience in access devices, instrumentation and flex technology."

 

 

For further information please contact:

 

Surgical Innovations Group plc

www sigroupplc com

David Marsh, CEO

Tel: 0113 230 7597

Charmaine Day, CFO

 

 

 

Singer Capital Markets (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / Rachel Hayes / Michael Nothnagel

 

 

 

Walbrook PR (Financial PR & Investor Relations)

Tel: 020 7933 8780 or si@walbrookpr.com

Paul McManus / Lianne Applegarth

Mob: 07980 541 893 / 07584 391 303

    

 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

 

In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.

 

We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.

 

Further information

Further details of the Group's businesses and products are available on the following websites:

www.sigroupplc.com 

www.surginno.com 

www.elementalhealthcare.co.uk 

 

To receive regular updates by email, please contact si@walbrookpr.com

 

About CMR Surgical Limited | www.cmrsurgical.com

CMR Surgical (CMR) is a global medical devices company dedicated to transforming surgery with Versius®, a next-generation surgical robot.

 

Headquartered in Cambridge, United Kingdom, CMR is committed to working with surgeons, surgical teams and hospital partners, to provide an optimal tool to make robotic minimal access surgery universally accessible and affordable. With Versius, we are on a mission to redefine the surgical robotics market with practical, innovative technology and data that can improve surgical care.

 

Founded in 2014, CMR Surgical is private limited company backed by an international shareholder base.

 

About the Versius® Surgical Robotic System

Versius® resets expectations of robotic surgery. Versius fits into virtually any operating room set-up and integrates seamlessly into existing workflows, increasing the likelihood of robotic minimal access surgery (MAS). The small, portable and modular design of Versius allows the surgeon to only use the number of arms needed for a given procedure.

 

Biomimicking the human arm, Versius gives surgeons the choice of optimised port placement alongside the dexterity and accuracy of small fully-wristed instruments. With 3D HD vision, easy-to adopt instrument control and a choice of ergonomic working positions, the open surgeon console has the potential to reduce stress and fatigue and allows for clear communication with the surgical team. By thinking laparoscopically and operating robotically with Versius, patients, surgeons and healthcare professionals can all benefit from the value that robotic MAS brings.

 

Versius also captures meaningful data with its wider digital ecosystem to support a surgeon's continuous learning. Through the Versius Connect app, Versius Trainer and CMR clinical registry, the Versius system unleashes can generate a wealth of insights with the ultimate goal of supporting improvements in surgical care.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PRLGZGMFNRNGZZM
Date   Source Headline
22nd Apr 20243:34 pmRNSHolding(s) in Company
19th Apr 20246:25 pmRNSHolding(s) in Company
18th Apr 20247:01 amRNSFinal Results
18th Apr 20247:00 amRNSNew exclusive UK distribution agreements secured
9th Apr 20247:00 amRNSDirectorate Change & Notice of Results
29th Jan 20247:00 amRNSYear-end 2023 Trading Update
19th Dec 20237:00 amRNSDirectorate Change
5th Dec 20237:00 amRNSDirectorate Change
19th Sep 20237:00 amRNSHalf-year Report
6th Sep 20237:00 amRNSTrading Update and Notice of Results
27th Jun 202312:12 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement
26th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
25th May 202311:11 amRNSDirector/PDMR Shareholding - Replacement
25th May 20237:00 amRNSDirector/PDMR Shareholding
22nd May 20237:00 amRNSDirectorate changes and board succession planning
29th Mar 20237:00 amRNSFinal Results
3rd Mar 20237:00 amRNSNotice of Results and Investor Presentation
23rd Jan 20237:00 amRNSYear-end Trading Update
21st Sep 20227:00 amRNSHalf-year Report
2nd Sep 20227:00 amRNSNotice of Interim Results
27th Jun 20223:15 pmRNSResult of AGM
27th Jun 20227:00 amRNSAGM Trading Statement
25th May 20227:00 amRNSPosting of 2021 Annual Report & Accounts
9th May 202212:41 pmRNSDirector/PDMR Shareholding
23rd Mar 20227:00 amRNSFinal Results
21st Mar 20227:00 amRNSProduct launch in partnership with CMR Surgical
10th Mar 20227:00 amRNSNotice of Annual Results
17th Jan 20227:00 amRNSYear-end Trading Update
15th Nov 20217:00 amRNSChanges to Board Structure & CFO Appointment
10th Nov 20215:43 pmRNSGrant of Options
15th Sep 20217:00 amRNSHalf-year Report
27th Aug 20217:00 amRNSNotice of Interim Results
9th Jul 20212:29 pmRNSDirector/PDMR Shareholding
22nd Jun 20215:26 pmRNSResult of AGM
22nd Jun 20217:00 amRNSAGM Trading Statement
21st Jun 20217:00 amRNSWithdrawal of AGM Resolution
21st May 20217:00 amRNSPosting of Annual Report& Accounts & Notice of AGM
25th Mar 20217:00 amRNSFinal Results
22nd Mar 20217:00 amRNS3-year Exclusive UK distribution agreement
8th Mar 20217:00 amRNSNotice of annual results
15th Feb 20217:00 amRNS5-year USA distribution agreement
9th Feb 20217:00 amRNSLaunch of the Green Surgery Challenge
8th Jan 20217:00 amRNSDistalmotion’s Dexter Robot receives CE Mark
7th Jan 20217:00 amRNSFuture board change
21st Dec 20207:00 amRNSTrading update
17th Dec 20207:00 amRNSUS distribution agreement signed with Adler
7th Dec 20203:00 pmRNSReplacement of Auditor
2nd Dec 20207:00 amRNSProduct launch for Cellis Breast
25th Nov 20207:00 amRNSCentre for Sustainable Healthcare collaboration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.